ライフサイエンスコーパス: matrix metalloproteinase inhibitor

1 ed hepatitis, even after pretreatment with a matrix metalloproteinase inhibitor.

2 he SDC4 ectodomain, mimicking the effects of matrix metalloproteinase inhibitors.

3 restored bone resorption in the presence of matrix metalloproteinase inhibitors.

4 These data support the notion of combining matrix metalloproteinase inhibitors and cytotoxic agents

5 th movement can be inhibited with the use of matrix metalloproteinase inhibitors, and suggests a mech

6 p (SAR) studies of a series of proline-based matrix metalloproteinase inhibitors are described.

7 lN/LPS- or Con A-induced hepatitis, and that matrix metalloproteinase inhibitors are ineffective in p

8 Sensitivity to known matrix metalloproteinase inhibitors as well as to the en

9 The addition of a matrix metalloproteinase inhibitor attenuated NKp46 down

10 rthermore, treatment with the broad-spectrum matrix metalloproteinase inhibitor batimastat (BB94) or

11 It is likely that adjuvant use of matrix metalloproteinase inhibitors can significantly en

12 antiangiogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazol

13 However, administration of a matrix metalloproteinase inhibitor exacerbates liver inj

14 In vitro, the matrix metalloproteinase inhibitor FN-439 promoted survi

15 Daily administration of the broad-spectrum matrix metalloproteinase inhibitor Galardin for 3 days i

16 bited in both isotypes by the broad-spectrum matrix metalloproteinase inhibitor, galardin (GM 6001).

17 Here we report that a matrix metalloproteinase inhibitor, GM-6001, improves su

18 Interestingly, the matrix metalloproteinase inhibitor GM6001 (ilomastat), w

19 lease of EGFR ligands, as the broad-spectrum matrix metalloproteinase inhibitor GM6001 could inhibit

20 ibiting ectodomain shedding of Dsg2 with the matrix metalloproteinase inhibitor GM6001 resulted in ac

21 tes the growth suppression properties of the matrix metalloproteinase inhibitor GM6001.

22 97, the HB-EGF neutralizing antibody, or the matrix metalloproteinase inhibitor GM6001.

23 with methylprednisolone and a broad-spectrum matrix metalloproteinase inhibitor (GM6001) did not deve

24 ptor (EGFR) inhibitor (tyrphostin AG1478), a matrix metalloproteinase inhibitor (GM6001), or a hepari

25 Recently, a class of matrix metalloproteinase inhibitors has been identified

26 Interferons, matrix metalloproteinase inhibitors, imatinib and gefiti

27 General matrix metalloproteinase inhibitors limited the resorpti

28 ell invasion, the combination of TMZ and the matrix metalloproteinase inhibitor marimastat (MRM) in p

29 lso were accelerated with the broad-spectrum matrix metalloproteinase inhibitor Marimastat, which may

30 idal obstruction syndrome, establishing that matrix metalloproteinase inhibitors may be a therapeutic

31 The hypothesis that matrix metalloproteinase inhibitors may be useful for ex

32 Matrix metalloproteinase inhibitors (MMPIs) reduce blood

33 and 3-mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designe

34 oMFA) for a novel series of piperazine-based matrix metalloproteinase inhibitors (MMPIs).

35 nd FasL-converting enzyme, can be blocked by matrix metalloproteinase inhibitors (MMPIs).

36 sclerosis using technetium-99m-labeled broad matrix metalloproteinase inhibitor (MPI) and to determin

37 Technetium-99m-labeled matrix metalloproteinase inhibitor (MPI) was used for th

38 ed to elucidate the effect of doxycycline, a matrix metalloproteinase inhibitor, on cardiac injury an

39 and vascular endothelial growth factor) and matrix metalloproteinase inhibitor (plasminogen activato

40 matrix metalloproteinases with a broad-based matrix metalloproteinase inhibitor prevented LV dilation

41 ng directional filopodial extension, whereas matrix metalloproteinase inhibitors prevented sprout ext

42 Administration of matrix metalloproteinase inhibitors prevented the signs

43 Doxycycline, a matrix metalloproteinase inhibitor, prevented matrix met

44 have demonstrated that treating tumors with matrix metalloproteinase inhibitors results in tumor red

45 uction of mitogenic signaling by PDGF-B in a matrix metalloproteinase inhibitor-sensitive fashion.

46 F impaired ARPE-19 migration toward HGF in a matrix metalloproteinase inhibitor-sensitive manner.

47 Thus, localized induction of endogenous matrix metalloproteinase inhibitors, such as TIMP-4, hol

48 Interferons, matrix metalloproteinase inhibitors, thalidomide, bevaci

49 mulated the search for a number of synthetic matrix metalloproteinase inhibitors that could serve as

50 remote and border zones at 3 months, and the matrix metalloproteinase inhibitor TIMP-4 increased dram

51 vidence suggests that elevated levels of the matrix metalloproteinase inhibitor, tissue inhibitor of

52 The ability of several specific matrix metalloproteinase inhibitors to reduce outflow fa

53 When BB-94, a matrix metalloproteinase inhibitor, was added to the cul

54 Doxycycline, a nonselective matrix metalloproteinases inhibitor, was reported to imp

55 tide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied.

56 Ilomastat, agents initially characterized as matrix metalloproteinase inhibitors which are in early s

57 ed by local delivery of Ilomastat, a general matrix metalloproteinase inhibitor, with the use of ethy